Smith+Nephew
Global medical devices for orthopedics
Data Science Intern - AI Center of Excellence
About the job
- Currently enrolled in a bachelor's, master's, or doctoral program in Data Science, Mathematics, Artificial Intelligence, Computer Science, Computer Engineering, or another relevant engineering discipline.
- No previous professional experience is required; academic experience using machine learning tools is expected.
- Strong coding skills in Python, R, MATLAB, or a similar data science programming language.
- Familiarity with machine learning libraries such as Scikit-learn, TensorFlow, NumPy, Pandas, PyTorch, or Keras.
- Strong understanding of data analytics techniques and the ability to implement analytical approaches.
- Ability to work independently and contribute effectively to a collaborative, fast-paced, multidisciplinary environment.
- Ability to collaborate with geographically distributed teams and colleagues from a range of backgrounds.
- Strong written and verbal communication skills.
- Research the latest generation of artificial intelligence models and explore their potential applications.
- Obtain, prepare, and clean training datasets.
- Develop feature encodings and implement machine learning methods.
- Analyze and validate models using statistical techniques.
- Create rapid proofs of concept and prototypes using data.
- Develop interfaces for exploring and using artificial intelligence solutions.
- Collaborate with colleagues across disciplines and locations to deliver enhancements to products.
About the company
Smith+Nephew is a global medical technology company that designs and makes medical devices for orthopaedics, sports medicine, and advanced wound care. Its products help surgeons treat joints and soft tissues and support patient recovery, including knee repair systems, single-use negative pressure wound therapy devices, and other extremity orthopaedic products. These devices are used in hospitals and clinics to perform procedures and support healing, often after surgery or injury. The company differentiates itself with a broad, worldwide product portfolio and collaborations with healthcare organizations to improve care and efficiency for patients and providers. Its goal is to improve patient outcomes, streamline medical procedures, and expand access to advanced medical solutions around the world.
Company Size
10,001+
Company Stage
IPO
Headquarters
Watford, United Kingdom
Founded
1856
Get referred to Smith+Nephew
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 2026 revenue reached $1.5 billion, and full-year guidance stayed intact on May 6.
- New launches in 2026 include CORI XT, FLOW FLEXTEND, and ALLEVYN COMPLETE CARE.
- August 2026 H1 results showed 4.6% growth, $200 million efficiency savings, and $500 million buyback.
What critics are saying
- Reuters on August 4, 2026 cut revenue guidance to around 4% after weak U.S. knees.
- Smith+Nephew’s finance chief John Rogers exits September 30, 2026, creating leadership churn.
- A March 2026 humeral nail recall and older hip litigation expose recurring quality risk.
What makes Smith+Nephew unique
- Smith+Nephew’s CORI XT robotics spans knee, shoulder, and future hip workflows.
- Its ASC Solutions bundles facility design, financing, and clinical enablement for outpatient surgery.
- ALLEVYN, RENASYS, and LEAF create a broad wound-care platform with measurable outcomes.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Holidays
Flexible Work Hours
Parental Leave
Fertility Treatment Support
Family Planning Benefits
Tuition Reimbursement
Wellness Program
Mental Health Support
Volunteer Time Off
Home Office Stipend
Phone/Internet Stipend
Discounted Stock Options
Health Savings Account/Flexible Spending Account
Employee Assistance Program
PTO/vacation?
Paid Sick Leave
Company News
Smith & Nephew has issued $700 million in senior notes with a 5.750% coupon maturing in 2036, netting $690.9 million after underwriting fees. The FTSE 100 medical technology firm will primarily use proceeds to fund a tender offer for its existing 2.032% senior notes due 2030, with remaining funds allocated to general corporate purposes. The refinancing replaces lower-yield debt with higher-coupon notes, reflecting current credit market conditions. BofA Securities, J.P. Morgan Securities, Mizuho Securities USA, and SMBC Nikko Securities America managed the transaction, which closed on 11 September 2026. Founded in Hull in 1856, Smith & Nephew operates across orthopaedics, sports medicine, ENT, and advanced wound management. The company employs approximately 17,000 people across 100 countries and reported annual sales of $6.2 billion in 2025.
Corient Private Wealth LP purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,871 shares of the medical equipment provider’s stock, valued at approximately $1,999,000. Other large investors […]
Smith+Nephew has launched the FLOW FLEXTEND COBLATION Wand, a new radiofrequency resection device designed for complex hip procedures. The device features an adjustable-angle tip that provides enhanced joint access and tissue targeting in difficult-to-reach hip, knee, and shoulder anatomies. The wand incorporates Smith+Nephew's FLOW~IQ technology, which automatically balances saline outflow with COBLATION energy. Its design includes a precision electrode with an adjustable tip that improves access to targeted tissues whilst facilitating insertion and removal. The angle adjustment mechanism allows surgeons to set the desired position without continuous manual control. Early surgeon feedback has been positive, with users highlighting improved versatility in the central compartment and precise tissue preservation capabilities compared to existing instruments.
Smith+Nephew has launched ASC Solutions, an enterprise strategy designed to help ambulatory surgery centres optimise costs, improve quality and enhance performance. The initiative provides ASCs with access to clinical expertise, procedural technologies and data analytics to support growth and patient outcomes in value-based care settings. The company is expanding its ASC ONE delivery model into an integrated platform that simplifies centre development and accelerates facility readiness. ASC ONE coordinates services including facility design, construction, financing and clinical enablement through a single point of contact. Smith+Nephew has partnered with STERIS Unity Health Centers, Brasfield & Gorrie, Ghafari and Hopper Healthcare to provide expertise across the ASC lifecycle. The model enables physician-led organisations and health systems to streamline vendor management whilst reducing complexity and improving execution timelines.
Smith+Nephew has completed the first clinical cases using its next-generation CORI XT Handheld Robotics Platform for knee and shoulder arthroplasty. The platform is designed as a single handheld robotics system for various orthopaedic procedures, including partial to revision knee, hip, and anatomic and reverse shoulder surgeries. The first shoulder arthroplasty cases were performed at Duke Health by Dr Christopher Klifto, who used CORI SHOULDER Handheld Robotic Arthroplasty with the AETOS Shoulder System. Dr Bertrand Kaper subsequently completed the first CORI XT shoulder cases in an ambulatory surgery centre setting in Scottsdale, Arizona. The platform supports both hospital and ambulatory surgical centre environments, with a compact footprint tailored to different facility needs. Smith+Nephew's approach aims to enhance surgeon expertise whilst maintaining clinical control and workflow efficiency.